000304583 001__ 304583
000304583 005__ 20250916115009.0
000304583 0247_ $$2doi$$a10.1002/ijc.70152
000304583 0247_ $$2pmid$$apmid:40938250
000304583 0247_ $$2ISSN$$a0020-7136
000304583 0247_ $$2ISSN$$a1097-0215
000304583 037__ $$aDKFZ-2025-01906
000304583 041__ $$aEnglish
000304583 082__ $$a610
000304583 1001_ $$00000-0003-2415-527X$$aFabian, Alexander$$b0
000304583 245__ $$aQuality of life in cancer patients at the end of radiotherapy compared to a general population sample in Germany.
000304583 260__ $$aBognor Regis$$bWiley-Liss$$c2025
000304583 3367_ $$2DRIVER$$aarticle
000304583 3367_ $$2DataCite$$aOutput Types/Journal article
000304583 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1757942298_18238
000304583 3367_ $$2BibTeX$$aARTICLE
000304583 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304583 3367_ $$00$$2EndNote$$aJournal Article
000304583 500__ $$aepub
000304583 520__ $$aGermany has one of the highest cancer incidence rates in Europe. Radiotherapy is essential for patients with cancer as 50% have an evidence-based indication for radiotherapy. However, it is unknown how health-related quality of life (HRQoL) of cancer patients undergoing radiotherapy compares to the general population in Germany. Therefore, we conducted a secondary analysis by pooling cross-sectional individual-level data from a multicenter cohort of cancer patients (n = 1052) undergoing radiotherapy across Germany and a normative sample from the German general population (n = 1006). We used the EORTC QLQ-C30 to measure global HRQoL (range: 0-100). Higher scores indicate higher HRQoL. We used ANOVA for univariable and ANCOVA with predefined covariates for multivariable analyses. As per univariable analysis, cancer patients had significantly lower global HRQoL compared with the general population (mean [M] = 54.6 vs. M = 65.9; p < .001). This difference was smaller but persisted in the multivariable analysis (M = 56.5 vs. M = 63.5; p < .001). Multivariable analyses stratified by education showed that HRQoL was only lower in cancer patients with medium (M = 56.2 vs. M = 63.0; p < .001) or high education (M = 57.0 vs. M = 66.5; p < .001) compared with the general population. The minimal important difference threshold of seven points was only met in the group with high education. In conclusion, there may be a meaningful gap in HRQoL of cancer patients at the end of radiotherapy compared with the general population, mainly in patients with higher educational levels. Upon validation, this would highlight the need for supportive care and optimized radiotherapy strategies to eventually close the HRQoL gap.
000304583 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000304583 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304583 650_7 $$2Other$$ageneral population
000304583 650_7 $$2Other$$aneoplasms
000304583 650_7 $$2Other$$aquality of life
000304583 650_7 $$2Other$$aradiotherapy
000304583 7001_ $$aRühle, Alexander$$b1
000304583 7001_ $$aLiegl, Gregor$$b2
000304583 7001_ $$aDomschikowski, Justus$$b3
000304583 7001_ $$aTrommer, Maike$$b4
000304583 7001_ $$aFerdinandus, Simone$$b5
000304583 7001_ $$aBecker, Jan-Niklas$$b6
000304583 7001_ $$aWurschi, Georg$$b7
000304583 7001_ $$aBoeke, Simon$$b8
000304583 7001_ $$aSonnhoff, Mathias$$b9
000304583 7001_ $$aGrott, Christoph$$b10
000304583 7001_ $$0P:(DE-HGF)0$$aKäsmann, Lukas$$b11
000304583 7001_ $$aSchneider, Melanie$$b12
000304583 7001_ $$aFreitag-Wolf, Sandra$$b13
000304583 7001_ $$aNicolay, Nils H$$b14
000304583 7001_ $$aKrug, David$$b15
000304583 7001_ $$00000-0001-6185-9423$$aNolte, Sandra$$b16
000304583 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.70152$$gp. ijc.70152$$pnn$$tInternational journal of cancer$$vnn$$x0020-7136$$y2025
000304583 909CO $$ooai:inrepo02.dkfz.de:304583$$pVDB
000304583 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000304583 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000304583 9141_ $$y2025
000304583 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-17$$wger
000304583 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-17$$wger
000304583 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-17
000304583 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-17
000304583 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-17
000304583 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-17
000304583 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-17
000304583 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-17
000304583 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-17
000304583 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-17
000304583 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-17
000304583 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2024-12-17
000304583 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2024-12-17
000304583 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK Koordinierungsstelle München$$x0
000304583 980__ $$ajournal
000304583 980__ $$aVDB
000304583 980__ $$aI:(DE-He78)MU01-20160331
000304583 980__ $$aUNRESTRICTED